U.S. markets closed

Coherus BioSciences, Inc. (CHRS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.45-0.46 (-5.82%)
At close: 04:00PM EDT
7.45 0.00 (0.00%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close7.91
Bid7.40 x 800
Ask7.41 x 900
Day's Range7.24 - 7.70
52 Week Range7.24 - 19.32
Avg. Volume889,400
Market Cap576.801M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.75
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CHRS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Coherus BioSciences, Inc.
    CHRS: Raising target price to $9.00COHERUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • GlobeNewswire

    Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

    - Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the appointment of cancer immunotherapy leader Jill O’Donnell-Tormey, Ph.D., to its Board of Directors. Dr. O’Donnell-Tormey will also serve on the Nominating and Corporate Governance Committee of the Boa

  • Simply Wall St.

    Shareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past week

    Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...

  • GlobeNewswire

    Coherus BioSciences Management to Present at Upcoming Investor Conferences

    REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m. ETUBS Global Healthcare Conference on Tuesday, May 24 at 2:00 p.m. ETH.C. Wainwright Global Investment Conference on Wednesday, May 25 at 9:00 a.m. ET Audio webcasts of these presentations will be available on the inve